Brought to you by 
Medtronic gets license to DreaMed's artificial pancreas IP
01 Feb 2023
Executive Summary
In its first alliance, DreaMed Diabetes licensed Medtronic PLC exclusive worldwide rights to develop and market products that incorporate the MD-Logic artificial pancreas algorithm.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Medical Devices
- Monitoring Equipment & Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medtronic gets license to DreaMed's artificial pancreas IP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice